Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Hypertension


Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

May 1st 2022

The dapagliflozin-induced plasma volume contraction may contribute to the initial SBP reduction, while a reduction in SNS activity may contribute to the persistent SBP reduction (Cardiovascular Diabetology)

Categories: Hypertension, Medication, News
Tags: dapagliflozin, exenatide, Type 2 Diabetes

Categories: Hypertension, Medication
Tags: dapagliflozin, exenatide, Type 2 Diabetes

Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study

January 27th 2022

Our findings suggest protective association of genetically proxied ACE inhibition with diabetes, while genetic proxies for BBs and CCBs possibly relate to an unfavourable metabolic profile (Diabetologia)

Categories: Cardiovascular, Hypertension, Medication, News
Tags: antihypertensives

Categories: Cardiovascular, Hypertension, Medication
Tags: antihypertensives

Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: a multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)

September 23rd 2021

Switching from DPP-4i to luseogliflozin decreased nighttime SBP and PR; moreover, BP circadian rhythm was improved (Diabetes Research and Clinical Practice)

Categories: Hypertension, Medication, News
Tags: luseogliflozin, SGLT2 inhibitors, Type 2 Diabetes

Categories: Hypertension, Medication
Tags: luseogliflozin, SGLT2 inhibitors, Type 2 Diabetes

Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial

September 14th 2021

Intensive BP treatment may reduce death and cardiovascular events among patients with type 2 diabetes receiving standard glycaemic treatment and without cognitive impairment (BMJOpen)

Categories: Hypertension, Management, Medication, News
Tags: intensive, Type 2 Diabetes

Categories: Hypertension, Management, Medication
Tags: intensive, Type 2 Diabetes

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes

June 30th 2021

The cumulative evidence from the recent cardiovascular outcome trials suggests that the effects of GLP-1R activation have a beneficial effect on blood pressure and cardiovascular diseases. However, a robust meta-analysis is needed to compare the controversial results of the different papers in the current literature (Journal of Diabetes Research)

Categories: Cardiovascular, Hypertension, Medication, News
Tags: DPP4 inhibitors, GLP1

Categories: Cardiovascular, Hypertension, Medication
Tags: DPP4 inhibitors, GLP1

Blood pressure levels and cardiovascular risk according to age in patients with diabetes mellitus: a nationwide population-based cohort study

October 21st 2020

In a cohort of hypertensive patients who had DM but no history of cardiovascular disease, lower BP was associated with lower risk of cardiovascular events especially at the age of < 70. However, low BP < 130–139/80–89 mmHg was not associated with decreased cardiovascular risk, it may be better to keep the BP of 130–139/80–89 mmHg at the age of ≥ 70 (Cardiovascular Diabetology)

Categories: Hypertension, News
Tags: AGE

Categories: Hypertension
Tags: AGE

The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes

May 20th 2020

In persons with T2DM, intensive SBP lowering decreased the risk of cardiovascular composite end point irrespective of baseline DBP in the setting of standard glycemic control. Hence, low baseline DBP should not be an impediment to intensive SBP lowering in patients with T2DM treated with guidelines recommending standard glycemic control (Diabetes Care)

Categories: Hypertension, News
Tags: Type 2 Diabetes

Categories: Hypertension
Tags: Type 2 Diabetes

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus

April 2nd 2020

Treatment with GLP‐1RA and SGLT2i led to significant reductions in BP in patients with type 2 diabetes mellitus. Weight reduction was significantly and independently associated with BP reductions in GLP‐1RA treatment and SGLT2i treatment (JAHA)

Categories: Hypertension, News
Tags: GLP‐1RA, HbA1c, SGLT2i

Categories: Hypertension
Tags: GLP‐1RA, HbA1c, SGLT2i

The cross‐sectional association between diabetes and orthostatic hypotension in community‐dwelling older people

November 26th 2019

Over one‐fifth of older people with diabetes had orthostatic hypotension. Recovery of DBP is related to dynamic changes in total peripheral resistance and impairment of this baroreflex‐mediated response may explain the higher prevalence in diabetes (Diabetic Medicine)

Categories: Hypertension, News
Tags: hypotension, orthostatic

Categories: Hypertension
Tags: hypotension, orthostatic

Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease

November 3rd 2019

Our results confirmed that blood pressure management status after treatment with SGLT2 inhibitors influences the extent of change in urinary albumin-creatinine ratio. Stricter blood pressure management is needed to allow the renoprotective effects of sodium-glucose cotransporter 2 inhibitors (Journal of Diabetes Research)

Categories: Hypertension
Tags: CKD, SGLT2 inhibitors

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

October 7th 2019

Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD and mortality (Cardiovascular Diabetology)

Categories: Hypertension, News
Tags: GLP1

Categories: Hypertension
Tags: GLP1

New – Hypertension in adults: diagnosis and management added to T2D guidelines

September 3rd 2019

This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively (NICE)

Categories: Hypertension, News
Tags: NICE

Categories: Hypertension
Tags: NICE

Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes

August 15th 2019

Our results suggest that BPV might provide additional information rather than mean blood pressure on the risk of cardiovascular disease in patients with type 2 diabetes (Diabetes, Obesity and Metabolism)

Categories: Hypertension, News
Tags: Type 2 Diabetes

Categories: Hypertension
Tags: Type 2 Diabetes

The association between fasting plasma glucose and glycated hemoglobin in the prediabetes range and future development of hypertension

April 30th 2019

Our study demonstrates that FPG in the prediabetes range, albeit not glycated hemoglobin, is independently and significantly associated with future development of HTN. Therefore, our findings further highlight the pivotal predictive role of IFG for HTN development as opposed to the limited independent role of abnormal HbA1c levels (Cardiovascular Diabetology)

Categories: Hypertension, News
Tags: FPG, HbA1c

Categories: Hypertension
Tags: FPG, HbA1c

Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis

April 19th 2019

Our data indicate that intensive BP lowering treatment provides greater benefits than less intensive treatment among patients with type 2 diabetes mellitus. Further studies are required to more clearly evaluate the benefits and harms of BP targets below those currently recommended with intensive BP lowering treatment (PLOS ONE)

Categories: Hypertension, News
Tags: Type 2 Diabetes

Categories: Hypertension
Tags: Type 2 Diabetes

C-reactive protein and blood pressure variability in type 2 hypertensive diabetic patients

March 12th 2019

In patients with diabetes and hypertension, higher CRP levels are linked to cardiometabolic derangements, although they are not associated with increased BP variability (Blood Pressure Monitoring)

Categories: Hypertension, News
Tags: Type 2 Diabetes

Categories: Hypertension
Tags: Type 2 Diabetes

Managing hypertension in people of African origin with diabetes: Evaluation of adherence to NICE Guidelines

January 29th 2019

This study provides insight into adherence to NICE guidance for managing hypertension in African origin patients with diabetes. Further work should be done to explore the effects of hypertension in this ethnic group and if there is a need for a more refined management guideline (Primary Care Diabetes)

Categories: Hypertension, News
Tags: African, NICE

Categories: Hypertension
Tags: African, NICE

24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study

December 4th 2018

Non-severely obese older diabetes patients with uncontrolled nocturnal hypertension showed significant BP reductions without marked reductions in glucose with the addition of empagliflozin to existing antihypertensive and antidiabetic therapy. Use of SGLT2 inhibitors in specific groups (e.g. those with nocturnal hypertension, diabetes, and high salt sensitivity) could help reduce the risk of heart failure and cardiovascular mortality (Circulation)

Categories: Hypertension, News
Tags: nocturna;, SGLT2 inhibitors

Categories: Hypertension
Tags: nocturna;, SGLT2 inhibitors

Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus

October 30th 2018

These data suggest that a >30% serum creatinine increase that coincides with lower blood pressure values should not directly lead to a reduction in antihypertensive medication in patients with type 2 diabetes mellitus (Hypertension)

Categories: Hypertension, News
Tags: creatinine, Type 2 Diabetes

Categories: Hypertension
Tags: creatinine, Type 2 Diabetes

Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Population-Based Retrospective Cohort Study

May 22nd 2018

Our findings support a SBP treatment target of 140 mmHg and suspect no risk reduction attenuation on CVD for lower SBP targets (<120 or <130 mmHg) for most patients with uncomplicated T2DM (Diabetes Care)

Categories: Hypertension, News
Tags: Type 2 Diabetes

Categories: Hypertension
Tags: Type 2 Diabetes
  • 1
  • 2
  • 3
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaBoehringer IngelheimNovo NordiskNapp Diabetes

Silver Sponsors

Abbott Diabetes CareAbout Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership